Serina CEO awarded 10,100 shares at $1.93

Serina Therapeutics, Inc. reported that Chief Executive Officer Steven A. Ledger acquired 10,100 shares of common stock as a grant/award on May 26, 2026.

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported that Chief Executive Officer Steven A. Ledger acquired 10,100 shares of common stock as a grant/award on May 26, 2026. The award is recorded at $1.93 per share, and his directly held common stock after this transaction totals 10,100 shares.

Insider Trade Summary

Grant/Award: 10,100 shares

Grant/Award 1 txn

Insider LEDGER STEVEN A

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,100	$1.93	$19K

Holdings After Transaction: Common Stock — 10,100 shares (Direct)

Footnotes (1)

1. F1. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.87 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

Key Figures

Shares granted: 10,100 shares Grant price: $1.93 per share Direct holdings after grant: 10,100 shares

3 metrics

Shares granted 10,100 shares Non-derivative common stock grant on May 26, 2026

Grant price $1.93 per share Reported value for the 10,100-share award

Direct holdings after grant 10,100 shares Total common stock directly held by CEO after transaction

Key Terms

Form 4, grant/award acquisition, non-derivative, weighted average purchase price

4 terms

Form 4 regulatory

"Serina Therapeutics disclosed this insider transaction in a Form 4 filing."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

grant/award acquisition financial

"The filing describes the action as a grant/award acquisition of common stock."

non-derivative financial

"The 10,100-share transaction is reported as a non-derivative common stock holding."

weighted average purchase price financial

"A footnote references a weighted average purchase price across multiple transactions."

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Serina Therapeutics (SER) disclose in this Form 4 filing?

Serina Therapeutics disclosed that CEO Steven A. Ledger received a grant of 10,100 shares of common stock. The non-derivative award was recorded at $1.93 per share, bringing his directly held common stock position to 10,100 shares following the transaction.

How many Serina Therapeutics (SER) shares did the CEO acquire?

CEO Steven A. Ledger acquired 10,100 shares of Serina Therapeutics common stock. These shares were reported as a grant or award acquisition, increasing his directly held common stock holdings to a total of 10,100 shares after the transaction disclosed in the Form 4.

What was the reported price per share in the Serina Therapeutics CEO grant?

The reported price per share for the CEO’s 10,100-share grant was $1.93. This figure reflects the value used in the Form 4 disclosure for the non-derivative common stock award received by Steven A. Ledger on May 26, 2026.

What is Steven A. Ledger’s Serina Therapeutics shareholding after this Form 4?

After this reported transaction, Steven A. Ledger directly holds 10,100 shares of Serina Therapeutics common stock. The Form 4 indicates that these shares result entirely from the grant or award acquisition reported for May 26, 2026.

Is the Serina Therapeutics CEO transaction an open-market buy or a grant?

The transaction is reported as a grant or award acquisition, not an open-market purchase. The Form 4 uses transaction code “A” and describes the action as a grant/award acquisition of 10,100 non-derivative common shares at a reported value of $1.93 per share.

Does this Serina Therapeutics Form 4 show any share sales by the CEO?

No share sales are reported in this Form 4. The filing shows only a single non-derivative transaction coded as an acquisition by grant or award, adding 10,100 common shares to Steven A. Ledger’s directly held position with no dispositions disclosed here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 03:55 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEDGER STEVEN A

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		A		10,100	A	$1.93(1)	10,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.87 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

Remarks:

	Steven A. Ledger	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)